疑似快速进展性痴呆患者中自身免疫性脑炎诊断标准的表现
这项观察性队列研究在两家三级中心纳入2016至2024年间261例疑似快速进展性痴呆成人患者,评估Graus可能自身免疫性脑炎(AE)标准的诊断表现。该标准诊断AE的敏感性89%、特异性96%、准确率94%;在AE患者中,高龄、启动免疫调节治疗时间较长及使用利妥昔单抗与进展为自身免疫性痴呆独立相关。
要点
- Graus可能AE标准在疑似快速进展性痴呆中诊断AE的敏感性89%、特异性96%、准确率94%。
- 72例存活AE患者中47例(65%)认知障碍持续超过3个月,符合自身免疫性痴呆标准。
- 高龄、启动免疫调节治疗延迟及使用利妥昔单抗与进展为自身免疫性痴呆独立相关。
核心结论
- Graus可能AE标准能可靠识别疑似快速进展性痴呆中由AE所致的患者。
- 在AE患者中,高龄、启动免疫调节治疗延迟及使用利妥昔单抗(作为严重或难治性AE的替代指标)与进展为自身免疫性痴呆独立相关。
- 这些发现适用于在专科转诊中心评估的患者,并需在更广泛场景中确认。
研究设计与样本
- 观察性队列研究,纳入2016至2024年在华盛顿大学圣路易斯和梅奥诊所杰克逊维尔两家三级中心评估的≥18岁疑似快速进展性痴呆患者。
- 共纳入261例患者,平均年龄61.1岁,46%为女性,83%为非西班牙裔白人。
- 由独立评审者根据临床数据、脑影像、脑电图和生物体液指标作出共识诊断,并以此评估Graus可能AE标准的诊断表现。
- 在AE患者中采用多变量逻辑回归模型识别与进展为自身免疫性痴呆独立相关的因素。
主要发现
- 261例疑似快速进展性痴呆患者中74例(28%)诊断为AE。
- Graus可能AE标准诊断AE的敏感性89%、特异性96%、准确率94%。
- 2例AE患者在症状起病3个月内死亡。
- 72例存活AE患者中47例(65%)认知障碍持续超过3个月,符合提出的自身免疫性痴呆标准。
- 多变量分析中,高龄(每增加10岁OR 1.4,95%CI 1.0-1.9)、启动免疫调节治疗时间较长(每延迟1个月OR 1.4,95%CI 1.1-1.9)及使用利妥昔单抗(OR 4.3,95%CI 1.2-15.1)与自身免疫性痴呆独立相关。
关键数值与推荐
- Graus可能AE标准诊断AE的敏感性89%、特异性96%、准确率94%。
- 自身免疫性痴呆定义为认知障碍持续超过3个月,72例存活AE患者中47例(65%)符合。
临床怎么用
- 原文未据此给出推荐。
局限性
- 这些发现适用于在专科转诊中心评估的患者,并需在更广泛场景中确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: The Graus criteria for possible autoimmune encephalitis (AE) are increasingly used to identify patients most likely to benefit from autoantibody testing and empiric immunotherapy. However, the performance of Graus criteria in patients with suspected rapidly progressive dementia (RPD) is unknown. We aimed to determine the diagnostic performance of the Graus criteria for possible AE in patients with suspected RPD and to identify the factors associated with progression to autoimmune dementia (AiD). METHODS: In this observational cohort study, patients ≥18 years with suspected RPD were enrolled and evaluated at 2 tertiary care centers (Washington University in St. Louis, MO, and Mayo Clinic Jacksonville, FL) from 2016 to 2024. Clinical data, brain imaging, electroencephalograms, and biofluid measures were reviewed, and consensus diagnoses were assigned by independent reviewers. We evaluated the diagnostic performance of the Graus criteria for possible AE against the consensus diagnosis. Among patients with AE, multivariable logistic regression models were used to identify factors independently associated with progression to AiD. RESULTS: Two hundred sixty-one patients with suspected RPD were enrolled (mean age 61.1 years, 46% female, 83% non-Hispanic White), including 74 patients (28%) with AE. The Graus criteria for possible AE demonstrated 89% sensitivity, 96% specificity, and 94% accuracy for the diagnosis of AE in patients with suspected RPD. Two patients with AE died within 3 months of symptom onset. Cognitive impairment persisted beyond 3 months in 47 of 72 surviving patients with AE (65%), meeting proposed criteria for AiD. In multivariable analysis, older age (odds ratio [OR] 1.4 per decade, 95% CI 1.0-1.9), longer time to initiation of immunomodulatory treatments (OR 1.4 per month, 95% CI 1.1-1.9), and treatment with rituximab (OR 4.3, 95% CI 1.2-15.1) were independently associated with AiD. DISCUSSION: The Graus criteria for possible AE reliably identified patients with suspected RPD due to AE. In patients with AE, older age, delays in the initiation of immunomodulatory therapies, and rituximab use (a proxy for severe/refractory AE) were independently associated with progression to AiD. These findings apply to patients evaluated at specialized referral centers and warrant confirmation in broader settings. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that the Graus criteria accurately distinguish AE from other causes of RPD.
引用
- Piura YD, Elgenidi A, Tipton PW, et al. Performance of Diagnostic Criteria for Autoimmune Encephalitis in Patients With Suspected Rapidly Progressive Dementia. Neurology. 2026. PMID: 43008255. doi:10.1212/WNL.0000000000218783
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。